Sat Kartar Shopping Limited, now operating as Sat Kartar Life Limited, announced the outcome of its Extra-Ordinary General Meeting (EGM) held on May 13, 2026. The meeting was conducted virtually through Video Conferencing (VC) and Other Audio Visual Means (OAVM), commencing at 10:00 A.M. and concluding at 10:32 A.M. IST. Shareholders unanimously passed both special resolutions concerning the issuance of equity shares and warrants to non-promoter categories.

EGM Proceedings and Participation

The meeting was chaired by Mr. Ved Prakash, Managing Director of the company. A total of 14 shareholders were present, holding 45,72,278 equity shares, representing 29.04% of the total shareholding. Mr. Devender Kumar Arora, Chief Financial Officer, briefed the attendees on the company's future vision and growth prospects. The requisite quorum was present, and the meeting was conducted in accordance with regulatory requirements.

Remote E-Voting Details

The company provided a remote e-voting facility through the CDSL platform. This facility was open from May 10, 2026, at 09:00 A.M. IST to May 12, 2026, at 05:00 P.M. IST. Shareholders holding shares as of the cut-off date of Wednesday, May 06, 2026, were eligible to vote. Mr. Vivek Rawal, Proprietor of M/s. Rawal & Co., was appointed as the Scrutinizer to oversee the voting process.

Resolution Results

Both special resolutions were passed with 100% of the votes cast in favour. The total votes polled were 1,04,35,956, with no votes recorded against either resolution. The detailed voting outcomes are summarized below:

Regulatory Compliance

The results and scrutinizer's report were submitted to the National Stock Exchange of India Limited pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure was signed by Sonal Seth, Company Secretary & Compliance Officer, on May 13, 2026. The proceedings will be hosted on the company's website and CDSL's e-voting portal.

Sat Kartar Shopping Limited, now operating as Sat Kartar Life Limited (formerly known as Sat Kartar Shopping Limited), has submitted the transcript of its H2 and FY26 Earnings Conference Call to the National Stock Exchange of India Limited, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. The filing, dated May 09, 2026, covers the company's performance for the half year and financial year ended March 31, 2026, and includes detailed management commentary on financial results, strategic initiatives, and future growth plans.

Earnings Conference Call Overview

The earnings conference call was held on Thursday, May 07, 2026 at 04:00 P.M. IST, moderated by Mr. Pawan Bhatia of Nuvama Wealth PCG and Mr. Ayush Divecha of Merlin Capital Advisors. The session featured Mr. Manprit Singh Chadha, Founder and Chief Operating Officer, who presented the company's financial performance and strategic direction.

Financial Performance Highlights

Management reported strong financial performance for FY26, with revenue crossing the ₹200 crore mark — a key milestone set at the time of the company's IPO. The following key metrics were highlighted during the call:

Mr. Chadha noted that the transition phase in H1 — which included factory setup, the Plantomed acquisition, and hospital development — had impacted working capital and cash generation. However, he stated that most parameters have stabilised and improved on an H1-to-H2 basis, with the exception of inventory days, which increased marginally by 12 to 15 days.

Strategic Initiatives and Business Expansion

The company outlined several key strategic developments that are expected to drive growth going forward:

Hospital Business: Sat Kartar Life has operationalised its first 30-bed Ayurveda hospital in Delhi. The hospital, still in early stages with bed utilisation below 10%, is targeting a daily revenue breakeven of ₹1 lakh and was generating approximately ₹50,000 per day at the time of the call. The company is targeting 300 beds by the end of FY27 and 1,000 beds by FY28, with a capital expenditure benchmark of approximately ₹4 lakh per bed (capex component), totalling approximately ₹40 crore for 1,000 beds.

Jeena Sikho Collaboration: Sat Kartar Life has entered into a non-exclusive partnership with Jeena Sikho, which operates approximately 2,800 Ayurveda hospital beds primarily in North India. Under the arrangement, Sat Kartar will route North India patient inquiries to Jeena Sikho's clinical outlets in exchange for a revenue share of approximately 15%. In South India — specifically Tamil Nadu, Karnataka, and Andhra Pradesh — Sat Kartar will open its own branded hospitals, potentially co-powered with Jeena Sikho's clinical expertise, for which Jeena Sikho will charge a management fee. Customer data in South India will remain with Sat Kartar Life.

Manufacturing and Subsidiaries: The company's in-house capsule and powder manufacturing facility is operational, with a total capex of approximately ₹1 crore to ₹1.25 crore including the gestation period. The 100% acquisition of Plantomed (US operations) is complete, with product range set and marketplace accounts being established. The company currently has three subsidiaries — Ajooni Life Sciences (nutraceuticals), Plantomed (low-ticket diabetes products), and Sat Kartar Ocean (advertising, not yet operational) — with a fourth US subsidiary pending RBI approval for overseas direct investment.

AI Initiatives: The company has begun deploying AI tools and reported a 4 to 5% improvement in ROI from current trials, with further improvement expected as the initiative scales.

Revenue Guidance and Margin Outlook

Management provided the following forward-looking revenue and margin guidance based on current business trajectory:

Mr. Chadha clarified that the ₹300 crore and ₹500 crore revenue targets pertain exclusively to the product business, with hospital revenues representing an additional upside. He noted that the company currently has approximately ₹45 crore in the bank to fund the first phase of hospital expansion, with subsequent phases to be funded through internal cash generation and, if required, debt — with no plans for further equity dilution at this stage.

Regulatory Compliance and Filing Details

The transcript is available on the company's official website at www.satkartar.in and can be directly accessed via the link provided in the regulatory filing. The disclosure was submitted by Sonal Seth, Company Secretary and Compliance Officer (Membership No. F13949), from the company's registered office at 603, 6th Floor, Mercantile House, KG Marg, New Delhi – 110001.

Source: None/Company/INE0NB801022/da5bc9ff65784925.pdf